Serveur d'exploration Stress et Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Combined efficacy of oseltamivir, isoprinosine and ellagic acid in influenza A(H3N2)-infected mice.

Identifieur interne : 000A14 ( Main/Exploration ); précédent : 000A13; suivant : 000A15

Combined efficacy of oseltamivir, isoprinosine and ellagic acid in influenza A(H3N2)-infected mice.

Auteurs : Elitsa L. Pavlova [Bulgarie] ; Lora S. Simeonova [Bulgarie] ; Galina A. Gegova [Bulgarie]

Source :

RBID : pubmed:29241072

Descripteurs français

English descriptors

Abstract

Influenza pathogenesis comprises a complex cascade of impaired cellular processes resulting from the viral replication and exaggerated immune response accompanied by reactive oxygen species (ROS) burst and oxidative stress, destructing membranous structures and tissues. By classical virological and biochemical methods we compared and evaluated the therapeutic effects of 2.5mg/kg/day of the antiviral drug - oseltamivir (OS), 500mg/kg/day of the immune modulator - isoprinosine (IP) and 500mg/kg/day of the antioxidant agent ellagic acid (EA) with a focus on their combined activities in influenza H3N2 virus-infected mice. The survival, lung pathology and titers, as well as the oxidative stress biomarker thiobarbituric acid reactive substances (TBARS) in the lungs, liver and blood plasma, correlated to the activities of the antioxidant enzymes superoxide dismutase (SOD) and glutathione reductase (GR) were assessed. We found that the viral inhibitor applied together with the immune modulator and the antioxidant exhibited strong therapeutic effects on the survival of the influenza-challenged mice. That effect was mostly pronounced for the triple combination - protection index (PI) of 75.2%, mean survival time (MST) extended by 5.8 days compared to the PBS control and significant reduction of the lung titers by 1.38 Δlg; 2.3 scores lower lung pathology and 8 times reduction of the accumulated TBARS in the lungs and liver on the 5-th day p.i. The enzymatic assays revealed that this combination demonstrated very good protection against the damaging superoxide radicals (83% efficiency of SOD, in comparison to healthy controls 100%). The double combinations of OS with IP and EA also showed protective effects according to the virological analysis - PI of 53.1% and 54.5%. Ten times higher GR activity was observed when the combination EA+OS and monotherapy of EA were applied (96% in comparison to healthy controls 100%). The best antioxidant effect in blood plasma was observed in the EA+IP group - 4 times reduction in the TBARS-content compared to infected controls but it did not have any efficacy on the survival and lung injury.

DOI: 10.1016/j.biopha.2017.12.014
PubMed: 29241072


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Combined efficacy of oseltamivir, isoprinosine and ellagic acid in influenza A(H3N2)-infected mice.</title>
<author>
<name sortKey="Pavlova, Elitsa L" sort="Pavlova, Elitsa L" uniqKey="Pavlova E" first="Elitsa L" last="Pavlova">Elitsa L. Pavlova</name>
<affiliation wicri:level="3">
<nlm:affiliation>Biophysics & Medical Physics, Sofia University "St. Kliment Ohridski", 5 James Boucher Blvd., 1164, Sofia, Bulgaria. Electronic address: elli_pavlova@abv.bg.</nlm:affiliation>
<country xml:lang="fr">Bulgarie</country>
<wicri:regionArea>Biophysics & Medical Physics, Sofia University "St. Kliment Ohridski", 5 James Boucher Blvd., 1164, Sofia</wicri:regionArea>
<placeName>
<settlement type="city">Sofia</settlement>
<region nuts="2">Sofia-ville (oblast)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Simeonova, Lora S" sort="Simeonova, Lora S" uniqKey="Simeonova L" first="Lora S" last="Simeonova">Lora S. Simeonova</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bonchev Str., 1113, Sofia, Bulgaria.</nlm:affiliation>
<country xml:lang="fr">Bulgarie</country>
<wicri:regionArea>Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bonchev Str., 1113, Sofia</wicri:regionArea>
<placeName>
<settlement type="city">Sofia</settlement>
<region nuts="2">Sofia-ville (oblast)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gegova, Galina A" sort="Gegova, Galina A" uniqKey="Gegova G" first="Galina A" last="Gegova">Galina A. Gegova</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bonchev Str., 1113, Sofia, Bulgaria.</nlm:affiliation>
<country xml:lang="fr">Bulgarie</country>
<wicri:regionArea>Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bonchev Str., 1113, Sofia</wicri:regionArea>
<placeName>
<settlement type="city">Sofia</settlement>
<region nuts="2">Sofia-ville (oblast)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29241072</idno>
<idno type="pmid">29241072</idno>
<idno type="doi">10.1016/j.biopha.2017.12.014</idno>
<idno type="wicri:Area/PubMed/Corpus">000294</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000294</idno>
<idno type="wicri:Area/PubMed/Curation">000294</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000294</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000285</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000285</idno>
<idno type="wicri:Area/Ncbi/Merge">000898</idno>
<idno type="wicri:Area/Ncbi/Curation">000898</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000898</idno>
<idno type="wicri:Area/Main/Merge">000A15</idno>
<idno type="wicri:Area/Main/Curation">000A14</idno>
<idno type="wicri:Area/Main/Exploration">000A14</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Combined efficacy of oseltamivir, isoprinosine and ellagic acid in influenza A(H3N2)-infected mice.</title>
<author>
<name sortKey="Pavlova, Elitsa L" sort="Pavlova, Elitsa L" uniqKey="Pavlova E" first="Elitsa L" last="Pavlova">Elitsa L. Pavlova</name>
<affiliation wicri:level="3">
<nlm:affiliation>Biophysics & Medical Physics, Sofia University "St. Kliment Ohridski", 5 James Boucher Blvd., 1164, Sofia, Bulgaria. Electronic address: elli_pavlova@abv.bg.</nlm:affiliation>
<country xml:lang="fr">Bulgarie</country>
<wicri:regionArea>Biophysics & Medical Physics, Sofia University "St. Kliment Ohridski", 5 James Boucher Blvd., 1164, Sofia</wicri:regionArea>
<placeName>
<settlement type="city">Sofia</settlement>
<region nuts="2">Sofia-ville (oblast)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Simeonova, Lora S" sort="Simeonova, Lora S" uniqKey="Simeonova L" first="Lora S" last="Simeonova">Lora S. Simeonova</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bonchev Str., 1113, Sofia, Bulgaria.</nlm:affiliation>
<country xml:lang="fr">Bulgarie</country>
<wicri:regionArea>Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bonchev Str., 1113, Sofia</wicri:regionArea>
<placeName>
<settlement type="city">Sofia</settlement>
<region nuts="2">Sofia-ville (oblast)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gegova, Galina A" sort="Gegova, Galina A" uniqKey="Gegova G" first="Galina A" last="Gegova">Galina A. Gegova</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bonchev Str., 1113, Sofia, Bulgaria.</nlm:affiliation>
<country xml:lang="fr">Bulgarie</country>
<wicri:regionArea>Department of Virology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Georgi Bonchev Str., 1113, Sofia</wicri:regionArea>
<placeName>
<settlement type="city">Sofia</settlement>
<region nuts="2">Sofia-ville (oblast)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</title>
<idno type="eISSN">1950-6007</idno>
<imprint>
<date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antioxidants (pharmacology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Cell Line</term>
<term>Dogs</term>
<term>Drug Therapy, Combination (methods)</term>
<term>Ellagic Acid (pharmacology)</term>
<term>Influenza A Virus, H3N2 Subtype (drug effects)</term>
<term>Inosine Pranobex (pharmacology)</term>
<term>Lung (metabolism)</term>
<term>Lung (virology)</term>
<term>Madin Darby Canine Kidney Cells</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred ICR</term>
<term>Orthomyxoviridae Infections (drug therapy)</term>
<term>Orthomyxoviridae Infections (metabolism)</term>
<term>Oseltamivir (pharmacology)</term>
<term>Oxidation-Reduction (drug effects)</term>
<term>Oxidative Stress (drug effects)</term>
<term>Superoxide Dismutase (metabolism)</term>
<term>Thiobarbituric Acid Reactive Substances (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Acide ellagique (pharmacologie)</term>
<term>Animaux</term>
<term>Antioxydants (pharmacologie)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Association de médicaments ()</term>
<term>Cellules rénales canines Madin-Darby</term>
<term>Chiens</term>
<term>Infections à Orthomyxoviridae (métabolisme)</term>
<term>Infections à Orthomyxoviridae (traitement médicamenteux)</term>
<term>Inosine pranobex (pharmacologie)</term>
<term>Lignée cellulaire</term>
<term>Mâle</term>
<term>Oséltamivir (pharmacologie)</term>
<term>Oxydoréduction ()</term>
<term>Poumon (métabolisme)</term>
<term>Poumon (virologie)</term>
<term>Souris</term>
<term>Souris de lignée ICR</term>
<term>Sous-type H3N2 du virus de la grippe A ()</term>
<term>Stress oxydatif ()</term>
<term>Substances réactives à l'acide thiobarbiturique (métabolisme)</term>
<term>Superoxide dismutase (métabolisme)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Superoxide Dismutase</term>
<term>Thiobarbituric Acid Reactive Substances</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antioxidants</term>
<term>Antiviral Agents</term>
<term>Ellagic Acid</term>
<term>Inosine Pranobex</term>
<term>Oseltamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Oxidation-Reduction</term>
<term>Oxidative Stress</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Lung</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Drug Therapy, Combination</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Infections à Orthomyxoviridae</term>
<term>Poumon</term>
<term>Substances réactives à l'acide thiobarbiturique</term>
<term>Superoxide dismutase</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Acide ellagique</term>
<term>Antioxydants</term>
<term>Antiviraux</term>
<term>Inosine pranobex</term>
<term>Oséltamivir</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Infections à Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Lung</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Cell Line</term>
<term>Dogs</term>
<term>Madin Darby Canine Kidney Cells</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred ICR</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Association de médicaments</term>
<term>Cellules rénales canines Madin-Darby</term>
<term>Chiens</term>
<term>Lignée cellulaire</term>
<term>Mâle</term>
<term>Oxydoréduction</term>
<term>Souris</term>
<term>Souris de lignée ICR</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Stress oxydatif</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Influenza pathogenesis comprises a complex cascade of impaired cellular processes resulting from the viral replication and exaggerated immune response accompanied by reactive oxygen species (ROS) burst and oxidative stress, destructing membranous structures and tissues. By classical virological and biochemical methods we compared and evaluated the therapeutic effects of 2.5mg/kg/day of the antiviral drug - oseltamivir (OS), 500mg/kg/day of the immune modulator - isoprinosine (IP) and 500mg/kg/day of the antioxidant agent ellagic acid (EA) with a focus on their combined activities in influenza H3N2 virus-infected mice. The survival, lung pathology and titers, as well as the oxidative stress biomarker thiobarbituric acid reactive substances (TBARS) in the lungs, liver and blood plasma, correlated to the activities of the antioxidant enzymes superoxide dismutase (SOD) and glutathione reductase (GR) were assessed. We found that the viral inhibitor applied together with the immune modulator and the antioxidant exhibited strong therapeutic effects on the survival of the influenza-challenged mice. That effect was mostly pronounced for the triple combination - protection index (PI) of 75.2%, mean survival time (MST) extended by 5.8 days compared to the PBS control and significant reduction of the lung titers by 1.38 Δlg; 2.3 scores lower lung pathology and 8 times reduction of the accumulated TBARS in the lungs and liver on the 5
<sup>-th</sup>
day p.i. The enzymatic assays revealed that this combination demonstrated very good protection against the damaging superoxide radicals (83% efficiency of SOD, in comparison to healthy controls 100%). The double combinations of OS with IP and EA also showed protective effects according to the virological analysis - PI of 53.1% and 54.5%. Ten times higher GR activity was observed when the combination EA+OS and monotherapy of EA were applied (96% in comparison to healthy controls 100%). The best antioxidant effect in blood plasma was observed in the EA+IP group - 4 times reduction in the TBARS-content compared to infected controls but it did not have any efficacy on the survival and lung injury.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Bulgarie</li>
</country>
<region>
<li>Sofia-ville (oblast)</li>
</region>
<settlement>
<li>Sofia</li>
</settlement>
</list>
<tree>
<country name="Bulgarie">
<region name="Sofia-ville (oblast)">
<name sortKey="Pavlova, Elitsa L" sort="Pavlova, Elitsa L" uniqKey="Pavlova E" first="Elitsa L" last="Pavlova">Elitsa L. Pavlova</name>
</region>
<name sortKey="Gegova, Galina A" sort="Gegova, Galina A" uniqKey="Gegova G" first="Galina A" last="Gegova">Galina A. Gegova</name>
<name sortKey="Simeonova, Lora S" sort="Simeonova, Lora S" uniqKey="Simeonova L" first="Lora S" last="Simeonova">Lora S. Simeonova</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A14 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A14 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29241072
   |texte=   Combined efficacy of oseltamivir, isoprinosine and ellagic acid in influenza A(H3N2)-infected mice.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29241072" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a StressCovidV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021